| P50 | author | Marta Larrayoz | Q55163336 |
| | Graham Packham | Q61314663 |
| | Andrew Davies | Q86642400 |
| | Matthew D Blunt | Q91393428 |
| | Francesco Forconi | Q30303490 |
| | Freda K. Stevenson | Q39978824 |
| | Peter Johnson | Q42165364 |
| P2093 | author name string | Pamela B Conley | |
| | Jan A Burger | |
| | Anjali Pandey | |
| | Andrew J Steele | |
| | Jonathan C Strefford | |
| | Stefan Koehrer | |
| | Lindsay D Smith | |
| | Greg P Coffey | |
| | Alice Hayman | |
| | Jack Parnell | |
| | Rachel C Dobson | |
| | Sarah Wilmore | |
| P2860 | cites work | Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia | Q24599100 |
| | Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines | Q24616084 |
| | The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 |
| | Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib | Q27853011 |
| | The IL-4 receptor: signaling mechanisms and biologic functions | Q28198739 |
| | An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia | Q28257366 |
| | Idelalisib and rituximab in relapsed chronic lymphocytic leukemia | Q28306347 |
| | Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells | Q42446777 |
| | The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer | Q42704069 |
| | Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia | Q42802658 |
| | The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment | Q42934788 |
| | Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL). | Q45888142 |
| | B-cell receptor signaling in chronic lymphocytic leukemia. | Q50674847 |
| | Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL. | Q51702964 |
| | IL-4 enhances expression and function of surface IgM in CLL cells. | Q55026394 |
| | Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-beta | Q73062537 |
| | IL4 production and increased CD30 expression by a unique CD8+ T-cell subset in B-cell chronic lymphocytic leukaemia | Q74624168 |
| | FDA approves tofacitinib for rheumatoid arthritis | Q85643691 |
| | Loss of cooperativity of secreted CD40L and increased dose-response to IL4 on CLL cell viability correlates with enhanced activation of NF-kB and STAT6 | Q87876983 |
| | MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies | Q33419789 |
| | Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. | Q34026194 |
| | Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals | Q34184717 |
| | Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia | Q34504188 |
| | Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK. | Q34508337 |
| | Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia | Q34568840 |
| | Idelalisib: first global approval | Q35237924 |
| | Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib | Q35450520 |
| | Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation | Q35820367 |
| | CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia | Q35868355 |
| | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 |
| | Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia | Q36490049 |
| | A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia | Q36519986 |
| | Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice | Q36998859 |
| | B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. | Q37028635 |
| | Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor | Q38170076 |
| | Ibrutinib: first global approval | Q38181979 |
| | Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment | Q38550810 |
| | BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. | Q38776895 |
| | Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma. | Q38819065 |
| | The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1. | Q38826234 |
| | Activating STAT6 mutations in follicular lymphoma. | Q38937478 |
| | A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor | Q39285533 |
| | The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells | Q40069478 |
| | The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model | Q40957763 |
| | Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib | Q41601558 |
| | High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation | Q42184742 |
| | Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration | Q42221150 |
| | Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. | Q42399858 |
| | Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial | Q42399878 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2313-2324 | |
| P577 | publication date | 2016-10-03 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia | |
| P478 | volume | 23 | |